Abstracts Archive - Page 2041 of 2607 - ACR Meeting Abstracts

Abstract Number: 2906 • 2014 ACR/ARHP Annual Meeting
Systemic Delivery of Short Hairpin RNA Targeting Calcium Release-Activated Calcium Channel 3 Down-Regulates Severity of Collagen-Induced Arthritis
Shuang Liu¹, Takeshi Kiyoi², Shohei Watanabe³ and Kazutaka Maeyama¹, ¹Department of Pharmacology, Informational Biomedicine, Ehime University Graduate School of Medicine, Toon-shi, Ehime, Japan, ²Bioscience, Integrated Center for Sciences, Ehime University, Ehime, Japan, ³Japan Community Health Care Organization Uwajima Hospital, Ehime, Japan
Background/Purpose: In recent years, one widespread and potentially important Ca2+ channel, store-operated Ca2+-release-activated Ca2+ (CRAC) channel is raised in drug discovery for rheumatoid arthritis (RA).…
Abstract Number: 2907 • 2014 ACR/ARHP Annual Meeting
Loss of microRNA-146a Exacerbates Inflammatory Arthritis
Victoria Saferding¹, Antonia Puchner², Eliana Goncalvesalves³, Birgit Niederreiter⁴, Silvia Hayer⁴, Gernot Schabbauer⁵, Marije Koenders⁶, Josef Smolen¹, Kurt Redlich³ and Stephan Blueml³, ¹Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ⁵Vascular Biology and Thrombosis research, Medical University Vienna, Vienna, Austria, ⁶Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands
Background/Purpose: MicroRNA (MiR-) 146a is a key regulator of the innate immune response and has also been shown to suppress cancer development in myeloid cells.…
Abstract Number: 2908 • 2014 ACR/ARHP Annual Meeting
Flip Deficiency in Dendritic Cells Promotes Spontaneous Arthritis Mediated By Reduced Treg and Increased Autoreactive CD4⁺t Cells
Qiquan Huang¹, Harris R. Perlman², Robert Birkett³, Renee E. Doyle⁴, Deyu Fang⁵, G Kenneth.Haines⁶, William H. Robinson⁷, Syamal K. Datta⁸, Hyewon Phee⁹ and Richard M. Pope¹⁰, ¹Division of Rheumatology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Chicago, IL, ³Division of Rheumatology, Department od Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁴Medicine/Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Mount Sinai Hospital School of Medicine, New York, New York, NY, ⁷VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, ⁸Rheumatology Division, Northwestern University Feinberg School of Medicine, Chicago, IL, ⁹Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL, ¹⁰Rheumatology, Northwestern University Feinberg school of Medicine, Chicago, IL
Background/Purpose Flip (CFLAR) has been identified as a rheumatoid arthritis (RA) risk allele and is important in preventing death receptor mediated apoptosis of dendritic cells…
Abstract Number: 2909 • 2014 ACR/ARHP Annual Meeting
Tolerogenic Splenic IDO+ Dendritic Cells from the Mice Treated with Induced-Treg Cells Could Suppress Collagen-Induced Arthritis
Jie Yang¹, Huahua Fan² and Hejian Zou¹, ¹Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai 200040, China, Shanghai, China, ²Blood Engineering Laboratory, Shanghai Blood Center, Shanghai 200051, China, Shanghai, China
Background/Purpose As well known, Foxp3+ regulatory T cells play a crucial role in maintaining immune tolerance. It was reported that TGF-β-induced Tregs (iTregs) could retain…
Abstract Number: 2910 • 2014 ACR/ARHP Annual Meeting
Tofacitinib Facilitates the Expansion of Myeloid-Derived Suppressor Cells and Ameliorates Arthritis in SKG Mice
Keisuke Nishimura¹, Jun Saegusa¹, Fumichika Matsuki², Kengo Akashi¹, Goichi Kageyama¹ and Akio Morinobu¹, ¹Rheumatology and Clinical Immunology, Kobe University Graduate School of Medicine, Kobe, Japan, ²Department of Evidence-based Laboratory Medicine, Kobe University Graduate School of Medicine, Kobe, Japan
Background/Purpose Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells that are characterized by the co-expression of Gr1 and CD11b in mice. MDSCs suppress…
Abstract Number: 2911 • 2014 ACR/ARHP Annual Meeting
Clinical Outcomes of Early RA after 7 Years – Does T2T Approach Overcome Delay of Therapy?
Tuulikki Sokka¹, Hannu Kautiainen², Tuomas Rannio³, Juha Asikainen¹ and Pekka Hannonen¹, ¹Jyvaskyla Central Hospital, Jyväskylä, Finland, ²Medcare Oy, Äänekoski, Finland, ³Kuopio University Hospital, Kuopio, Finland
Background/Purpose: Early vs. delayed referral/start of therapy within 3-4 months has been shown beneficial for outcomes in rheumatoid arthritis (RA) (Lard et al. AM J…
Abstract Number: 2912 • 2014 ACR/ARHP Annual Meeting
Impact of Failure to Adhere to Treat-to-Target of Rheumatoid Arthritis in Real World Practice: Data from the International Rheumatoid Arthritis Biomarker Program
Walter P. Maksymowych^1,2, M. Østergaard³, O Elkayam⁴, R Landewé⁵, J Homik⁶, C Thorne⁷, M Backhaus⁸, S Shaikh⁹, G Boire¹⁰, M Larche¹¹, B Combe¹², T Schaeverbeke¹³, A Saraux¹⁴, G Ferraccioli¹⁵, M Dougados¹⁶, C Barnabe¹⁷, M Govoni¹⁸, PP Tak¹⁹, D. van Schaardenburg²⁰, D van der Heijde²¹, R Dadashova², E Hutchings², J Paschke² and Oliver FitzGerald²², ¹Medicine, University of Alberta, Edmonton, AB, Canada, ²CaRE Arthritis, Edmonton, AB, Canada, ³Copenhagen Center for Arthritis Research, Glostrup, Denmark, ⁴Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁵Amsterdam Rheumatology Center, Amsterdam, Netherlands, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Rheumatology/Immunology, Charite University Hospital, Berlin, Germany, ⁹Niagara Peninsula Arthritis Centre, Hamilton, ON, Canada, ¹⁰CHUS-Sherbrooke University, Sherbrooke, QC, Canada, ¹¹St Joseph's Healthcare Hamilton, Hamilton, ON, Canada, ¹²Immuno-Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ¹³Bordeaux University Hospital, Bordeaux, France, ¹⁴CHU Brest and EA 2216, UBO, Brest, France, ¹⁵Catholic University of The Sacred Heart, Rome, Italy, ¹⁶Hopital Cochin, Paris, France, ¹⁷University of Calgary, Calgary, AB, Canada, ¹⁸Universita di Ferrara, Ferrara, Italy, ¹⁹Academic Medical Center, Amsterdam, Netherlands, ²⁰Jan van Breemen Research Institute, Amsterdam, Netherlands, ²¹Leiden University Medical Center, Leiden, Netherlands, ²²St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose . There is limited data on adherence to treat-to-target (T2T) strategies in RA in real world-practice and the impact of failure to adopt this…
Abstract Number: 2913 • 2014 ACR/ARHP Annual Meeting
Does Corticosteroid Therapy at Disease Onset Influence Disease Progression of RA? Results from the Swiss Prospective Observational Cohort
Ruediger Mueller¹, Nazim Reshiti², Toni Kaegi³, Axel Finckh⁴, Hendrik Schulze-Koops⁵, Michael H. Schiff⁶ and Johannes von Kempis⁷, ¹Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Division of Rheumatology, St. Gallen, Switzerland, ³Division of Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁴Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁵Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ⁶School of Medicine, University of Colorado, Denver, CO, ⁷Rheumatology, St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland
Background/Purpose Anti-inflammatory and disease-modifying properties of glucocorticoids (GCs) have been demonstrated in patients with rheumatoid arthritis (RA). Better outcomes in trials by combinations of synthetic…
Abstract Number: 2914 • 2014 ACR/ARHP Annual Meeting
The Clinical and Radiographic Course of Early Undifferentiated Arthritis Under Treatment Is Not Dependent on the Amount of Erosions at Diagnosis. Results from the Swiss Prospective Observational Cohort
Ruediger Mueller¹, Toni Kaegi², Sarah Haile³ and Johannes von Kempis⁴, ¹Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Division of Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ³Division of Biostatistics, Institute for Social and Preventive Medicine,, University of Zurich, Switzerland, Zurich, Switzerland, ⁴Rheumatology, St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland
Background/Purpose To analyse whether early arthritis patients who do not fulfil the ACR/EULAR 2010 classification criteria for rheumatoid arthritis (RA) have a different course of…
Abstract Number: 2875 • 2014 ACR/ARHP Annual Meeting
Macrophage Expression of Hypoxia-Inducible Factor-2 Alpha Promotes Rheumatoid Arthritis Progression
Munitta Muthana^1,2, William Jacob Hardy³, Sarah Hawtree¹, Fiona Wright¹, Ursula Fearon⁴, DJ Veale⁵, Mauro Perretti⁶ and Anthony G. Wilson⁷, ¹Infection and Immunity, University of Sheffield, Sheffield, United Kingdom, ²Medical School, University of Sheffield, Sheffield, United Kingdom, ³University of Sheffield, Sheffield, United Kingdom, ⁴Dublin Academic Medical Centre, Translational Rheumatology Research Group, Dublin, Ireland, ⁵Consultant Rheumatologist, St. Vincent’s University Hospital, Dublin, Ireland, ⁶Biochemical Pharmaology, Barts and the London School of Medicine, London, United Kingdom, ⁷University College Dublin, Dublin, Ireland
Background/Purpose Hypoxia exists in many diseased tissues including arthritic joints, atherosclerotic plaques and malignant tumours. Macrophages accumulate in these hypoxic sites where they possess broad…
Abstract Number: 2876 • 2014 ACR/ARHP Annual Meeting
Interleukin-10 Receptor Blockade during Lcmv Infection Results in Macrophage Activation Syndrome-like Disease in Mice
Lehn K. Weaver¹ and Edward M. Behrens², ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Pediatric Rheumatology, Childrens Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Macrophage activation syndrome (MAS) is the rheumatic disease-associated member of a group of hyperinflammatory syndromes characterized by uncontrolled cytokine storm manifest as unremitting fevers,…
Abstract Number: 2877 • 2014 ACR/ARHP Annual Meeting
Novel Function of Tocilizumab As a Modulator of Interleukin-27-Mediated Anti-Inflammatory Responses
Misato Hashizume¹, Jun Kikuchi², Keiko Yoshimoto² and Tsutomu Takeuchi², ¹Product Research Department, Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
Background/Purpose The immunological roles of interleukin 27 (IL-27) have been reported in the function of regulatory T cells (Treg), monocytes and osteoclasts, and these cells…
Abstract Number: 2878 • 2014 ACR/ARHP Annual Meeting
G Protein Signaling Modulator 3 (GPSM3) Deficiency Is Protective in Inflammatory Arthritis Models and Altered GPSM3 Gene Products Correlate with Single Nucleotide Polymorphisms in Humans
Teresa K. Tarrant¹, D. Stephen Serafin², Elizabeth Sugg², Roman Timoshchenko², Matthew J. Billard², David P. Siderovski³ and Kristy Richards⁴, ¹Medicine/Rheumatology, Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, ³Physiology and Pharmacology, West Virginia University School of Medicine, Morgantown, WV, ⁴Medicine, Dept. of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC
Background/Purpose GPSM3, a newly described regulator of heterotrimeric G protein signaling, is selectively expressed in hematopoietic cells with high expression in monocytes. We have shown…
Abstract Number: 2879 • 2014 ACR/ARHP Annual Meeting
Epigallocatechin-3-Gallate (EGCG) Suppresses IL-1β-Induced IL-6 and IL-8 Synthesis By Selectively Inhibiting TAK1 Activation in Human Rheumatoid Arthritis Synovial Fibroblasts
Anil Singh¹, Sharayah Riegsecker², Sadiq Umar¹ and Salahuddin Ahmed¹, ¹Department of Pharmaceutical Sciences, Washington State University, Spokane, WA, ²Department of Pharmacology, University of Toledo, Toledo, OH
Background/Purpose: In rheumatoid arthritis (RA), the role of interleukin-1β (IL-1β) signaling proteins (IRAK-1/TAK-1/TRAF-6) proximal to IL-1 receptor in mediating proinflammatory response is not completely understood.…
Abstract Number: 2880 • 2014 ACR/ARHP Annual Meeting
Elevated Levels of Soluble Inflammatory Mediators and Lupus-Specific Connective Tissue Disease Questionnaire Scores Discern Unaffected First Degree Relatives of Lupus Patients from Unaffected Individuals Not Related to Lupus Patients
Melissa E. Munroe¹, Kendra A. Young², Jennifer Fessler³, Dustin Fife³, Diane L. Kamen⁴, Joel M. Guthridge³, Timothy B. Niewold⁵, Michael H. Weisman⁶, Mariko L. Ishimori⁶, Daniel J. Wallace⁷, David R. Karp⁸, John B. Harley⁹, Gary S. Gilkeson⁴, Jill M. Norris² and Judith A. James^10,11, ¹Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Epidemiology, Colorado School of Public Health, Aurora, CO, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine, Division of Rheumatology, Medical University of South Carolina, Charleston, SC, ⁵Division of Rheumatology and Department of Immunology, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁷Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁸Rheumatic Diseases Division, UT Southwestern Medical Center, Dallas, TX, ⁹Center for Autoimmune Genomics and Etiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Clinical Arthritis and Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹¹Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: Identifying populations at risk of SLE is essential to curtail inflammatory damage and select individuals for prevention trials. First-degree relatives (FDRs) of lupus patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].